Effects of Interferon-α Therapy on Immune Parameters in Immune Thrombocytopenic Purpura

References

• McMillan R. Chronic idiopathic thrombocytopenic pupura. N. Engl. J. Med 1981; 304: 1135–1147
   PubMed Web of Science ®Google Scholar
• Van Leeuwen E. F., Van der Ven J. T. H., Engelfriet C. P., von dem Borne A. E.G.K. Specificity of autoantibodies in autoimmune thrombocytopenia. Blood 1982; 59: 23–26
   PubMed Web of Science ®Google Scholar
• Szatowski N. S., Kunicki T. J., Aster R. H. Identification of glycoprotein Ib as a target for autoantibody in idiopathic (autoimmune) thrombocytopenic purpura. Blood 1986; 61: 2321–2326
   Google Scholar
• He R., Reid D. M., Jones C. E., Shulman N. R. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 1994; 83: 1024–1032
   PubMed Web of Science ®Google Scholar
• Mylvaganum R., Ahn Y. S., Harrington W. J., Kim C. I., Gratzner H. G. Differences in T cell subsets between men and women with idiopathic thrombocytopenic purpura. Blood 1985; 66: 967–972
   Google Scholar
• Peller S., Kaufman S., Shaked U. Immunoregulatory defect in patients with autoimmune thrombocytopenic purpura (ATP). Thymus 1986; 8: 361–367
   PubMedGoogle Scholar
• Garcia‐Suarez J., Prieto A., Reyes E., Manzano L., Merino J. L., Alvarez‐Mon M. The clinical outcome of autoimmune thrombocytopenic purpura patients is related to their T cell immunodeficiency. Brit. J. Haematol 1993; 84: 464–470
   Google Scholar
• Berchtold P., McMillan R. Therapy of chronic idiopathic thrombocytopenic purpura adults. Blood 1989; 74: 2309–2317
   PubMed Web of Science ®Google Scholar
• Proctor S. J., Jackson G., Carey P., Stark A. Short‐course alpha‐interferon therapy in severe unresponsive immune thrombocytopenic purpura. Lancet 1988; i: 947
   Google Scholar
• Proctor S. J. Alpha interferon therapy in the treatment of idiopathic thrombocytopenic purpura. Eur. J. Cancer 1991; 27(Suppl.4)S63–468
   Google Scholar
• Vianelli R., Catani L., Gugliotta L., Belmonte M. M., Cascione L., Colangeli V., et al. Recombinant alpha‐interferon 2b in the treatment of HIV‐related thrombocytopenia. AIDS 1993; 7: 823–827
   Google Scholar
• Ellis M. E., Neal K. R., Leen C. L. S., Newland A. C. Alfa‐2a recombinant interferon in HIV associated thrombocytopenia. Br. Med. J 1987; 295: 1519
   PubMedGoogle Scholar
• Lever A. M., Brook M. G., Yap I., Thomas H. C. Treatment of thrombocytopenia with alfa interferon. Brit. Med. J 1987; 295: 1519–1520
   PubMedGoogle Scholar
• Behrenbeck U., Riedel F., Rieger C. H. L. Increase in platelet count following short course therapy with recombinant alpha‐2b‐interferon in immune thrombocytopenic purpura in childhood. Pediatr. Allergy Immunol 1993; 4: 10–12
   Google Scholar
• Velu T., Delwiehe F., Gangii D., Monsier R., Fla‐ment J., Stryckmans B., et al. Therapeutic effect of human recombinant interferon‐alpha‐2c in essential thrombocythaemia. Oncology 1985; 42(suppl. I)10–14
   Google Scholar
• Giles F. J., Singer C. R. J., Gray A. G., Yong K. L., Brozovic M., Davies S. C., et al. Alpha‐interferon therapy for essential thrombocythaemia. Lancet 1988; ii: 70–72
   Google Scholar
• Bellucci S., Harousseau J. L., Brie P., Tobelem G. Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet 1988; ii: 960–961
   Google Scholar
• Gisslinger H., Ludwig H., Linkesch W., Chott A., Fritz E., Radaszkiewiez T. Long‐term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet 1989; i: 634–637
   Google Scholar
• Talpaz M., Kurzock R., Kantarjian H., O'Brien S., Gutterman J. U. Recombinant interferon‐alpha therapy of Philadelphia chromosome‐negative mycloproliferative disorders with thromboeytosis. Am. J. Med 1989; 86: 554–558
   PubMed Web of Science ®Google Scholar
• Gutterman J. U. Cytokine therapeutics: lessons from interferon alpha. [Review]. Proc. Natl. Acad. Sci. U.S.A 1994; 91: 1198–205
   PubMed Web of Science ®Google Scholar
• Neubauer R. H., Goldstein L., Rabin H., Stebbing N. Stimulation of in vitro immunoglobulin production by interferon‐alpha. Immunol 1985; 134: 299–304
   Google Scholar
• Fleisher T. A., Attallah A. M., Tosato G., Blaese M., Greene W. C. Interferon‐mediated inhibition of human polyclonal immunoglobulin synthesis. J. Immunol 1982; 129: 1099–1103
   PubMed Web of Science ®Google Scholar
• Pelton B. K., Denman A. M. Immunoregulatory effects of interferon‐alpha. I. Interferon‐alpha inhibits in vitro antibody synthesis by normal human lymphocytes. Clin. exp. Immunol 1985; 59: 398–404
   Google Scholar
• Peters M., Ambrus J. L., Zheleznyak A., Walling D., Hoofnagle J. H. Effect of interferon‐alpha on immunoglobulin synthesis by human B cells. J. Immunol 1986; 137: 3153–3157
   PubMed Web of Science ®Google Scholar
• Pene J., Rousset F., Briere F., Chretien I., Bonnefoy J. Y., Spits H., et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc. Natl. Acad. Sci. U.S.A 1988; 85: 6880–6884
   PubMed Web of Science ®Google Scholar
• Welsh R. M. Natural killer cells and interferon. [Review]. Critical Reviews in Immunology 1984; 5: 55–93
   Google Scholar
• Parronchi P., De Carli M., Manetti R., Simonelli C., Sampognaro S., Piccini M. ‐P., et al. IL‐4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Thl or Th2 human T cell clones. J. Immunol 1992; 149: 2977–2983
   PubMed Web of Science ®Google Scholar
• Romagnani S. Induction of Thl and Th2 responses: a key role for the 'natural' immune response?. Immunology Today 1992; 13: 379–381
   PubMedGoogle Scholar
• Kiefel V., Santoso S., Weisheit M., Mueller‐Eckhardt C. Monoclonal antibody‐specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet‐reactive antibodies. Blood 1987; 70: 1722–1726
   PubMed Web of Science ®Google Scholar
• Dickinson A. M., Proctor S. J., Jacobs E., Reid A. M., Walker W., Craft A. W., et al. Natural killer cell activity in childhood acute lymphoblastic leukaemia in remission. British Journal of Haematology 1985; 59: 45–53
   PubMed Web of Science ®Google Scholar
• Hazlewood M., Kumararatne D. S. The spleen? Who needs it anyway?. Clin. exp. Immunol 1992; 89: 321–329
   Google Scholar
• Romagnani S. Lymphokine production by human T cells in disease states. Annu. Rev. Immunol 1994; 12: 227–257
   PubMed Web of Science ®Google Scholar
• Goldman M., Druet P., Gleichmann E. TH2 cells in systemic autoimmunity: insights from allogeneic diseases and chemically‐induced autoimmunity. Immunology Today 1991; 12: 223–227
   PubMedGoogle Scholar
• Semple J. W., Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 1991; 78: 2619–2625
   PubMed Web of Science ®Google Scholar
• Del Prete G. F., de Carli M., Ricci M., Romagnani S. Helper activity for immunoglobulin synthesis of T helper type 1 (Th1) and Th2 human T cell clones: the help of Th1 clones is limited by their cytolytic capacity. J. Exp. Med 1991; 174: 809–813
   PubMed Web of Science ®Google Scholar
• Gruschwitz M. S., Peters K. P., Heese A., Stosiek N., Koch H. U., Hornstein O. P. Effects of interferon‐alpha‐2b on the clinical course, inflammatory skin infiltrates and peripheral blood lymphocytes in patients with severe atopic eczema. Int. Arch. Allergy. Appl. Immunol 1993; 101: 20–30
   Google Scholar
• Souillet G., Rousset F., Dc Vries J. E. Alpha‐interferon treatment of patient with hyper IgE syndrome. Lancet 1989; i: 1384
   Google Scholar
• Ferrick D. A., Schrenzel M. D., Mulvania T., Hsieh B., Ferlin W. G., Lepper H. Differential production of interferon‐gamma and interleukin‐4 in response to Th1‐ and Th2‐stimulating pathogens by gamma/delta T cells in vivo. Nature 1995; 373: 255–257
   PubMed Web of Science ®Google Scholar
• Lagoo A. S., Eldridge J. H., Lagoo‐Deenadaylan S., Black C. A., Ridwan B. U., Hardy K. J., et al. Peyer's patch CD8 + memory T cells secrete T helper type 1 and type 2 cytokines and provide help for immunoglobulin secretion. Eur. J. Immunol 1994; 24: 3087–3092
   Google Scholar
• Bordin J. O., Smith J. W., Hayward C. P. M. W. T. E., Wasi P., Kelton J. G. Bacterial infection‐associated improvement of platelet counts in two patients with chronic and unresponsive idiopathic thrombocytopenic purpura with normal platelet survival studies. Brit. J. Haematol 1995; 90: 332–335
   Google Scholar
• Ballem P. J., Segal G. M., Stratton J. R., Gernsheimer T., Adamson J. W., Slichter S. J. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. J. Clin. Invest 1987; 80: 33–40
   PubMed Web of Science ®Google Scholar
• Pancre V., Joseph M., Capron A., Wietzerbin J., Kurnierz J. ‐P., Vorng H., et al. Recombinant human interferon‐gamma induces increased IgE receptor expression on human platelets. Eur. J. Immunol 1988; 18: 829–832
   PubMed Web of Science ®Google Scholar
• Fujisawa K., Tani P., Piro L., McMillan R. The effect of therapy on platelet‐associated autoantibody in chronic immune thrombocytopenic purpura. Blood 1993; 81: 2872–2877
   PubMed Web of Science ®Google Scholar
• Semple J. W., Bruce S., Freedman J. Suppressed natural killer cell activity in patients with chronic autoimmune thrombocytopenic purpura. Am. J. Haematol 1991; 37: 258–262
   PubMed Web of Science ®Google Scholar
• Semple J. W., Freedman J. Natural killer cell numbers and activity in patients with chronic autoimmune thrombocytopenic purpura [letter; comment]. Blood 1994; 83: 870–871
   Google Scholar